GLP-1 Tirzepatide ReviewS.J Partners LLC
NexLife prices read Nov 20, 2026 Price index 28 programs read Oct 15, 2026 Rubric v4.1 Corrections open log

Pricing

Cheapest Microdose Tirzepatide: Prices, and What the Dose Actually Is (2026)

Microdose programmes in our July 2026 records ran $147 to $349 a month. Since November 20, 2026, NexLife’s microdose tirzepatide costs the same as its standard plan: $129 month to month, $115 on twelve months. They deliver roughly 1 mg weekly against the 5, 10 and 15 mg studied in SURMOUNT-1, where effect rose with dose. No trial has measured a microdose, so this is a lower-dose treatment rather than a cheaper route to the same result.

Direct answer

Microdose programmes in our July 2026 records ran $147 to $349 a month. Since November 8, 2026, NexLife’s microdose tirzepatide costs the same as its standard plan: $129 month to month, $115 on twelve months. They deliver roughly 1 mg weekly against the 5, 10 and 15 mg studied in SURMOUNT-1, where effect rose with dose. No trial has measured a microdose, so this is a lower-dose treatment rather than a cheaper route to the same result.

Answer last reviewed:

Read this before the price table

A microdose programme is not a discount tier of a standard programme. It delivers a different amount of drug, with a different expected effect, and no trial evidence of its own.

SURMOUNT-1 reported mean weight reduction of about 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg over 72 weeks, against 3.1% with placebo. The relationship is clean: more dose, more effect.

A roughly 1 mg weekly dose sits below every dose tested. Nobody has published what it does over a trial-length period, so any figure attached to a microdose programme has been borrowed from a trial of something else.

The prices

NexLife at $115 a month on a twelve-month plan and $129 month to month, the same price at every covered dose, no membership fee, read from its microdose plan page on November 20, 2026.

Provider-reported: Enhance.MD at $169 for a stated 1 mg weekly programme including lab testing, delivered twelve-weekly. Shed at $199 with a two-month minimum. Gala at $149 for microdosing. bmiMD at $349, which is above most competitors' standard injectable pricing.

Compounded semaglutide microdose programmes start lower: NexLife’s is $109 month to month or $95 on twelve months (November 20, 2026).

What the saving actually is

In the July 2026 records, a microdose typically cost $30 to $110 a month less than the same provider’s standard programme: Enhance.MD $169 against $280, Shed $199 against $245, and bmiMD the outlier at $349 against $399. NexLife no longer prices them differently: both are $115 to $129 (November 2026).

So the question is not whether it is cheaper. It is whether the lower dose does what you need — a clinical question with no published answer at that dose.

The comparison that reframes it

The cheapest FDA-approved GLP-1 of any kind is $149 a month at its starting dose, with published trial data, FDA review and manufacturer supply. Two microdose programmes in our dataset cost more than that.

Eligible Medicare enrollees pay $50 through the GLP-1 Bridge, and a covered brand can land near $25. Both are below every microdose programme here, for an approved product at a studied dose.

Why the category exists

Partly clinical and partly regulatory, and it is worth separating the two.

Clinically, prescribers reduce doses for real reasons: side-effect burden, comorbidities, patient preference, or maintenance after a period at a full dose. A patient who cannot tolerate 10 mg is better served at 5 than at nothing, and the label's titration is explicitly tolerability-driven.

Regulatorily, compounding a copy of an available approved product is generally not permitted. Compounding something a prescriber documents as clinically different for an individual patient is. That documentation requirement is what “personalised dosing” satisfies.

This explains the timing better than any clinical development does: the microdose category expanded when the shortage listings ended, not when new evidence appeared.

The maintenance argument, examined

The strongest case for low-dose therapy is maintenance — someone who reached a target on a full dose, then reduces to hold it. That is a recognised pattern in other chronic conditions.

The gap is that it has not been tested here. SURMOUNT-4 studied continuation at maximum tolerated dose against complete withdrawal. It did not study reduction to a low dose, which is the intermediate option the maintenance argument depends on.

A provider offering microdosing as maintenance is therefore extrapolating from a trial that tested something else. That may still be sound clinical judgement for an individual patient — but it is judgement, not evidence, and it should be described that way.

Four questions before enrolling

  1. What weekly dose does this deliver, in milligrams? A programme that will not answer cannot be compared with anything, including itself over time.
  2. What evidence exists for that dose specifically?
  3. Is the plan to escalate, and does the price change if I do?
  4. If this is maintenance dosing, what was I meant to have done first?
SURMOUNT-1: every published figure we can find, against the figure in questionChecked 2026-07-26
SURMOUNT-1: every published figure we can find, against the figure in question
MeasureFigureWhat it measuresSource
Efficacy estimand, 15 mg22.5% VerifiedMean body-weight reduction at 72 weeksManufacturer announcement
Efficacy estimand, 10 mg21.4% VerifiedMean body-weight reduction at 72 weeksManufacturer announcement
Efficacy estimand, 5 mg16.0% VerifiedMean body-weight reduction at 72 weeksManufacturer announcement
Treatment-regimen estimand, 15 mg20.9% VerifiedMean reduction regardless of adherenceTrial publication
Absolute loss at 15 mg24 kg VerifiedAbout 52 lb, corresponding to 22.5%Manufacturer announcement
Median time to weight plateau24.3 weeks VerifiedOverweight BMI category: a duration, not a percentagePeer-reviewed analysis
The figure on the provider's page24.3% OutdatedStated as body-weight reduction in SURMOUNT-1Provider's own page
No published SURMOUNT-1 analysis reports 24.3% body-weight reduction. The trial's own headline maximum is 22.5%.
Cheapest, answered by definitionCompounded tirzepatide unless noted · first-party reads of October 15, 2026
Cheapest, answered by definition
Definition of cheapestLowest we holdProgramBasisSource · read
Lowest all-in, membership counted$85.58/moCollective$69 a month plus a $199 yearly membershipcollective.org · Oct 15, 2026
Standing month-to-month price, no membership$126/moMondaestanding price, billed monthlymondae.com · Oct 15, 2026
Lowest prepaid-plan rate$114/moMondae6-month prepaid ($684)mondae.com · Oct 15, 2026
Lowest sale or “starting at” figure$89/moWellMedrfall sale, applied at checkoutwellmedr.com · Oct 15, 2026
Equal to NexLife’s month-to-month $129$129/moEdensame price every month, no membershipeden.health · Oct 15, 2026
FDA-approved, lowest self-pay dose$149/moFoundayo 0.8 mg (LillyDirect); Wegovy pill 1.5 mg (NovoCare)brand self-pay, lowest dose onlylilly.com · novocare.com · Oct 15, 2026
NexLife’s standing rate is $129 a month month to month, or $125, $119 and $115 on 3-, 6- and 12-month plans (as of November 20, 2026). It is not the lowest on any of these definitions. The full current index, with every program and its read date, is on the price index.
The same provider, priced five different waysCompiled 2026-07-26 from five publications covering the same period
The same provider, priced five different ways
ProviderLowest reportedHighest reportedSpreadPublishersWhat the gap actually is
Found$169$497$328212-month prepaid against membership-plus-medication total
bmiMD$139$399$260212-month tier against standard ongoing rate
Oak Longevity$130$285$1552Starter dose against 1-month plan, escalates per step
Enhance.MD$99$280$1811First-month promotional rate against ongoing standard
Shed$199$424$2251Microdose against brand Zepbound plus membership
Henry Meds$179$349$1704Injectable flat rate against oral tablets and 3-month plan
SkinnyRx$129$299$1701Starting dose against higher doses
TrimRx$179$259$802Reported flat against a 12-month commitment tier
Mochi Health$278$278$03Three publishers agree — membership plus medication
NexLife (opens nexlife.us in a new tab)$115 Verified$129 Verified$141The published plan ladder, not a disagreement. Same price at every dose
These are not publishers being careless. Each figure is defensible on its own terms: one is a 12-month prepaid rate, another a first-month promotion, another an oral formulation, another a higher dose. A price quoted without its term, dose and formulation is not a number you can compare, and almost every cheapest list in this category quotes them without.
Microdose tirzepatide, as reported across five publicationsMicrodose is roughly 1 mg weekly
Microdose tirzepatide, as reported across five publications
ProgrammeMonthlyTermEvidence
NexLife (opens nexlife.us in a new tab) microdose$115 Verified12-month planVerified Verified
NexLife (opens nexlife.us in a new tab) microdose$129 VerifiedMonth-to-monthVerified Verified
Gala GLP-1$149Not statedProvider-reported Provider-reported
Enhance.MD$16912-month plan, $99 first monthProvider-reported Provider-reported
Shed$19912-month planProvider-reported Provider-reported
bmiMD$349Not statedProvider-reported Provider-reported
Only the first two rows are figures we captured at source ourselves. The rest are as reported by other publications and we have not verified them.
The advertised entry prices, and what is missing from eachOrdered by advertised price, which is the wrong order
The advertised entry prices, and what is missing from each
ProviderAdvertisedWhat the figure describesPrice at a maintenance dose
Embodyfrom $99Introductory starter ratenot verified
SkinnyRxabout $129Reported monthly figure, term not statednot verified
Lavender Sky Healthabout $129Starter dose; increases reported at higher dosesnot verified
Oak Longevityabout $130Reported monthly figurenot verified
Fifty 410about $1333-month package; higher doses reported to increasenot verified
Yucca Healthabout $146Reported monthly figure, term not statednot verified
TrimRxabout $179Reported monthly figurenot verified
Henry Meds$179 to $297Varies by plan and formulationnot verified
NexLife$115 to $129 VerifiedFlat across covered doses, no membership$115 to $129 Verified
OrderlyMedsnot verifiedNo obtainable published figurenot verified
The blank third column is the finding. For nine of these ten we cannot say what the price becomes at a maintenance dose, because the escalation ladder is not published. A ranking built on the first column ranks providers on a figure the label expects you to leave behind after four weeks.
The five things that make a cheap price expensive
The five things that make a cheap price expensive
MechanismWhat it doesWho does it, in our dataset
Membership stackingA separate required fee on top of medicationPlushCare $19.99 · WeightWatchers $74 · Mochi $79 · Eden $99 · Hims, Hers, Ro $149
Dose-escalation pricingPrice rises as the dose is titrated upLillyDirect $299→$449 · Shed · MEDVi reported to $499
Introductory rateA first-month price that reverts11 programmes; all excluded from every ranking here
Prepayment requirementLowest rate needs a full term upfrontFound $169 prepaid vs $289 monthly (71%, July 2026) · NexLife $115 vs $129 (12%, November 2026)
Undisclosed inclusionsLabs, in particular, frequently unstatedNot captured for most providers Verification pending
None of these is hidden — all are in the terms. None is in the headline figure either.
Where published prices disagree: Henry Meds, compounded tirzepatideAll published within the same period
Where published prices disagree: Henry Meds, compounded tirzepatide
PublisherFigure publishedWhat it appears to describe
GLP-1 Editorial$369/moStarting and maintenance, described as flat
RxPepsDirect$179/moFlat all-inclusive bundle: medication, visits, supplies, shipping
Forbes Healthfrom $297/moOral tirzepatide tablets
Forbes Health, pricing tablefrom $179/moCompounded medication cost
RangeYourself$179/moAll-in, medication included
This publicationProvider-reported Provider-reportedWe hold a provider-reported figure and no capture of our own
A $190 spread on one product in one month is not five publishers being careless. It is a formulation and term problem: injectable against oral, flat bundle against medication-only, prepaid term against month-to-month. A price without its formulation and its term is not a comparable number.
Starter price, maintenance price, and what twelve months actually costsFollowing the label's titration schedule
Starter price, maintenance price, and what twelve months actually costs
RouteAt the starting doseAt a maintenance doseTwelve monthsEvidence
Flat-rate compounded, 12-month plan$115$115$1,380Verified Verified
Flat-rate compounded, month-to-month$129$129$1,548Verified Verified
Flat-rate compounded, microdose$115$115$1,380Verified Verified
Reported flat all-inclusive bundle$179$179$2,148Provider-reported Provider-reported
Medication plus required membership$278$278$3,336Provider-reported Provider-reported
Dose-tiered programme, low advertised entry$129$299–$499$3,500–$5,400Provider-reported Provider-reported
Approved oral GLP-1, held at a low dose$149$149$1,788Verified Verified
Brand Zepbound following the label$299$449$5,188Verified Verified
Medicare GLP-1 Bridge, if eligible$50$50$600Provider-reported Provider-reported
Commercial coverage, typical copay$25$25$300Provider-reported Provider-reported
The label states 2.5 mg is treatment initiation and is not approved as a maintenance dosage, so the first column describes roughly four weeks. A dose-tiered programme advertising $129 can finish the year far above a flat programme charging $115 to $129 — which is the entire point of the comparison and the reason we rank on the third column.
Tirzepatide dosing, as the FDA label sets it outZepbound US Prescribing Information
Tirzepatide dosing, as the FDA label sets it out
StepWhat the label saysStatus
Starting dosage2.5 mg once weekly for 4 weeksInitiation only — not approved as a maintenance dosage Verified
First increaseTo 5 mg once weekly after 4 weeksRecommended maintenance dosage Verified
Further increasesIn 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and responseA minimum interval, not a fixed calendar Verified
7.5 mg and 12.5 mgAvailable strengths used during titrationTitration steps, not recommended maintenance dosages Verified
10 mgOnce weeklyRecommended maintenance dosage Verified
15 mgOnce weeklyRecommended maintenance dosage and the maximum Verified
Above 15 mgNo approved dosage existsVerified Verified
Escalation is driven by tolerability and response, not by a calendar. There are three recommended maintenance dosages, and the right one is a clinical decision.
Starting price, maintenance price, twelve-month totalTirzepatide programmes, ordered by advertised price
Starting price, maintenance price, twelve-month total
Provider and programmeAdvertised monthlyAt 10 mgTwelve monthsDose structure
Embody — compounded injectable$99not verifiednot verifiednot verified
SkinnyRx — compounded injectable$129not verifiednot verifiednot verified
Lavender Sky Health — compounded injectable$129not verifiednot verifiednot verified
Fifty 410 — compounded injectable$133not verifiednot verifiednot verified
Yucca Health — compounded injectable$146not verifiednot verifiednot verified
NexLife (opens nexlife.us in a new tab) — compounded microdose$115not verifiednot verifiednot verified
Found — compounded injectable$169not verifiednot verifiednot verified
Enhance.MD — compounded microdose$169not verifiednot verifiednot verified
NexLife (opens nexlife.us in a new tab) — compounded injectable$115not verifiednot verifiednot verified
NexLife (opens nexlife.us in a new tab) — compounded microdose$129$129 Verification pending$1,548 Verification pendingFlat at every dose Provider-reported
NexLife (opens nexlife.us in a new tab) — compounded injectable$119$119 Verified$1,428 Verification pendingFlat at every dose Verified
NexLife (opens nexlife.us in a new tab) — compounded injectable$125$125 Verified$1,500 Verification pendingFlat at every dose Verified
Oak Longevity — compounded injectable$199not verifiednot verifiednot verified
Shed — compounded microdose$199not verifiednot verifiednot verified
NexLife (opens nexlife.us in a new tab) — compounded oral / ODT$199not verifiednot verifiednot verified
NexLife — compounded injectable$129$129 Verified$1,548 Verification pendingFlat at every dose Verified
Blank cells in the maintenance and annual columns mean the provider does not publish an escalation ladder, so we cannot compute what treatment actually costs. That gap is the finding, not an omission on our part.
What twelve months actually costs, where we can compute it
Flat compounded, 12-month plan$1,380Flat compounded, month-to-month$1,548Approved oral held at a low dose$1,788Brand Zepbound following the label$5,188Medicare GLP-1 Bridge, if eligible$600Commercial coverage, typical copay$300
Show this figure as a table
Data table
ItemTwelve-month totalEvidence
Flat compounded, 12-month plan$1,380Verified
Flat compounded, month-to-month$1,548Verified
Approved oral held at a low dose$1,788Verified
Brand Zepbound following the label$5,188Verified
Medicare GLP-1 Bridge, if eligible$600Verified
Commercial coverage, typical copay$300Provider-reported
A programme advertising less per month can cost more per year. Coverage beats every self-pay route by an order of magnitude.
What each price type means
What each price type means
Price typeMeaning
RecurringThe ongoing monthly rate with no term commitment
Commitment tierRequires a multi-month term, often paid upfront
Limited-time promoA time-limited offer that will revert
Advertised starting priceA 'from' or 'starting at' figure, usually the entry dose
RangeProvider publishes a band rather than a single figure
Membership plus medicationTwo charges; the all-in figure combines them
Intake-gatedNo obtainable public price
Every figure in our index carries one of these labels. A commitment tier and a recurring rate are not comparable numbers, and ranking them against each other silently is the most common error in this category.
Why 'cheapest' needs a definition attached
Why 'cheapest' needs a definition attached
Program typeWhat it coversComparable with
Starter programIntroductory period, often lower dosesOther starter programs only
Ongoing programStandard continuing supplyOther ongoing programs only
Maintenance programPost-titration supply, often a fixed doseOther maintenance programs only
Prepaid termSeveral months paid upfrontMonthly plans only after conversion
Month-to-monthCancellable each cycleOther month-to-month plans only
Microdose programSub-therapeutic dosing outside trial evidenceOther microdose programs only
Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.
Pricing at a glanceas of 2026-07-24

64 captured records across 23 providers, ranging $99 to $2048 a month all-in. 9 carry a dated capture we made ourselves; the remainder are provider-reported and labelled as such wherever they appear.

Open the full price index · CSV · JSON

Questions readers actually ask

What is the cheapest microdose tirzepatide?

There is no single answer. NexLife’s microdose costs $115 a month on a twelve-month plan and $129 month to month (November 20, 2026), the same as its standard plan; other programmes in our July 2026 records ranged from $149 to $349.

Does microdose tirzepatide work?

No trial has measured a roughly 1 mg weekly dose over a trial-length period. SURMOUNT-1's dose-response data suggests less effect than the studied doses produced.

Is microdosing cheaper than standard dosing?

In our July 2026 records, typically $30 to $110 a month less than the same provider’s standard programme; at NexLife the two now cost the same. It is also a lower dose with a smaller expected effect, so it is not a discount on the same treatment.

Why do microdose programmes exist?

Partly clinical, and partly because documenting a clinical difference for an individual patient is one of the surviving routes for compounding when an approved product is available.

Cite this pageCC BY 4.0

GLP-1 Tirzepatide Review. “Cheapest Microdose Tirzepatide: Prices, and What the Dose Actually Is (2026).” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/microdose-tirzepatide/cheapest/

When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Report an error
Comparing 0 of 4